sumatriptan


Also found in: Dictionary, Wikipedia.
Related to sumatriptan: Sumatriptan succinate

sumatriptan

 [soo″mah-trip´tan]
a selective serotonin receptor agonist used as the succinate salt in the acute treatment of migraine and cluster headaches; administered orally, subcutaneously, or intranasally.

sumatriptan

/su·ma·trip·tan/ (soo″mah-trip´tan) a selective serotonin receptor agonist used as the succinate salt in the acute treatment of migraine and cluster headaches.

sumatriptan

(so͞o′mə-trĭp′tn)
n.
A triptan drug, C14H21N3O2S, used also in the form of its succinate to treat migraine headache and cluster headache.

sumatriptan

A SEROTONIN antagonist drug that has been found effective in the symptomatic treatment of acute MIGRAINE. A brand name is Imigran.
References in periodicals archive ?
today announced that COMPASS, its Phase IIIb, cross-over clinical trial comparing the efficacy and safety of AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraine across multiple attacks, has been published and is available in hard copy at the 57[sup.
Individuals were randomly given either 1 ginger capsule of 250 mg or 50 mg of sumatriptan upon onset of headache.
9 in the sumatriptan and ginger treated groups respectively.
A burst of air delivers sumatriptan just under the skin in less than a second.
Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low.
These occurred more commonly when taking aspirin than when taking a placebo, and more commonly when taking 100 mg sumatriptan than when taking aspirin plus metoclopramide.
But a 100mg dose of sumatriptan was slightly better at delivering a pain-free response within two hours.
So far, the registry has amassed information on 761 pregnancies exposed to sumatriptan and 88 exposed to naratriptan.
The pregnancy registry did not contain any data on the exposure to the combination of sumatriptan and naproxen.
Over the 12 months ending June 30, Sumatriptan Succinate tablets had sales of $934 million, according to IMS Health.
The confidential terms of the settlement, which remain subject to government review, permit Par to sell generic versions of certain sumatriptan injection products with an expected launch date during GSK's sumatriptan pediatric exclusivity period which begins on August 6, 2008, but with the launch occurring not later than November 2008.
Today, there are seven triptans, including sumatriptan (Imitrex), zolmitriptan (Zomig) and eletriptan (Relpax).